Adult mice are unresponsive to AAV8-Gremlin1 gene therapy targeting the liver
Khatib Shahidi, Roxana (University of Gothenburg. Department of Molecular and Clinical Medicine)
M. Hoffmann, Jenny (University of Gothenburg. Department of Molecular and Clinical Medicine)
Hedjazifar, Shahram (University of Gothenburg. Department of Molecular and Clinical Medicine)
Bonnet, Laurianne (University of Gothenburg. Department of Molecular and Clinical Medicine)
K. Baboota, Ritesh (University of Gothenburg. Department of Molecular and Clinical Medicine)
Heasman, Stephanie (BioPharmaceuticals R&D. Bioscience Metabolism, Research and Early Development, Cardiovascular, Renal and Metabolism)
Church, Christopher (BioPharmaceuticals R&D. Bioscience Metabolism, Research and Early Development, Cardiovascular, Renal and Metabolism)
Elias Puigdomenech, Ivet (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular)
Bosch i Tubert, Fàtima (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular)
Boucher, Jeremie (BioPharmaceuticals R&D. Bioscience Metabolism, Research and Early Development, Cardiovascular, Renal and Metabolism)
Hammarstedt, Ann (University of Gothenburg. Department of Molecular and Clinical Medicine)
Smith, Ulf (University of Gothenburg. Department of Molecular and Clinical Medicine)

Data:	2021
Resum:	Gremlin 1 (GREM1) is a secreted BMP2/4 inhibitor which regulates commitment and differentiation of human adipose precursor cells and prevents the browning effect of BMP4. GREM1 is an insulin antagonist and serum levels are high in type 2 diabetes (T2D). We here examined in vivo effects of AAV8 (Adeno-Associated Viral vectors of serotype eight) GREM 1 targeting the liver in mature mice to increase its systemic secretion and also, in a separate study, injected recombinant GREM 1 intraperitoneally. The objective was to characterize systemic effects of GREM 1 on insulin sensitivity, glucose tolerance, body weight, adipose cell browning and other local tissue effects. Adult mice were injected with AAV8 vectors expressing GREM1 in the liver or receiving regular intra-peritoneal injections of recombinant GREM1 protein. The mice were fed with a low fat or high fat diet (HFD) and followed over time. Liver-targeted AAV8-GREM1 did not alter body weight, whole-body glucose and insulin tolerance, or adipose tissue gene expression. Although GREM1 protein accumulated in liver cells, GREM1 serum levels were not increased suggesting that it may not have been normally processed for secretion. Hepatic lipid accumulation, inflammation and fibrosis were also not changed. Repeated intraperitoneal rec-GREM1 injections for 5 weeks were also without effects on body weight and insulin sensitivity. UCP1 was slightly but significantly reduced in both white and brown adipose tissue but this was not of sufficient magnitude to alter body weight. We validated that recombinant GREM1 inhibited BMP4-induced pSMAD1/5/9 in murine cells in vitro, but saw no direct inhibitory effect on insulin signalling and pAkt (ser 473 and thr 308) activation. GREM1 accumulates intracellularly when overexpressed in the liver cells of mature mice and is apparently not normally processed/secreted. However, also repeated intraperitoneal injections were without effects on body weight and insulin sensitivity and adipose tissue UCP1 levels were only marginally reduced. These results suggest that mature mice do not readily respond to GREMLIN 1 but treatment of murine cells with GREMLIN 1 protein in vitro validated its inhibitory effect on BMP4 signalling while insulin signalling was not altered.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Teràpia gènica
Publicat a:	PloS one, Vol. 16 (february 2021) , ISSN 1932-6203

DOI: 10.1371/journal.pone.0247300
PMID: 33606810

17 p, 2.0 MB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats